Cargando…
Drug repurposing for breast cancer therapy: Old weapon for new battle
Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128772/ https://www.ncbi.nlm.nih.gov/pubmed/31550502 http://dx.doi.org/10.1016/j.semcancer.2019.09.012 |
_version_ | 1783516638389207040 |
---|---|
author | Aggarwal, Sadhna Verma, Sumit Singh Aggarwal, Sumit Gupta, Subash Chandra |
author_facet | Aggarwal, Sadhna Verma, Sumit Singh Aggarwal, Sumit Gupta, Subash Chandra |
author_sort | Aggarwal, Sadhna |
collection | PubMed |
description | Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development. Repositioning of old, clinically approved, off patent non-cancer drugs with known targets, into newer indication is like using old weapons for new battle. The advances in genomics, proteomics and information computational biology has facilitated the process of drug repurposing. Repositioning approach not only fastens the process of drug development but also offers more effective, cheaper, safer drugs with lesser/known side effects. During the last decade, drugs such as alkylating agents, anthracyclins, antimetabolite, CDK4/6 inhibitor, aromatase inhibitor, mTOR inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment. The repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer. The literature review suggest that serendipity plays a major role in the drug development. This article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment. The strategies as well as several examples of repurposed drugs are provided. The challenges associated with drug repurposing are discussed. |
format | Online Article Text |
id | pubmed-7128772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71287722020-04-08 Drug repurposing for breast cancer therapy: Old weapon for new battle Aggarwal, Sadhna Verma, Sumit Singh Aggarwal, Sumit Gupta, Subash Chandra Semin Cancer Biol Review Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development. Repositioning of old, clinically approved, off patent non-cancer drugs with known targets, into newer indication is like using old weapons for new battle. The advances in genomics, proteomics and information computational biology has facilitated the process of drug repurposing. Repositioning approach not only fastens the process of drug development but also offers more effective, cheaper, safer drugs with lesser/known side effects. During the last decade, drugs such as alkylating agents, anthracyclins, antimetabolite, CDK4/6 inhibitor, aromatase inhibitor, mTOR inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment. The repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer. The literature review suggest that serendipity plays a major role in the drug development. This article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment. The strategies as well as several examples of repurposed drugs are provided. The challenges associated with drug repurposing are discussed. Elsevier Ltd. 2021-01 2019-09-21 /pmc/articles/PMC7128772/ /pubmed/31550502 http://dx.doi.org/10.1016/j.semcancer.2019.09.012 Text en © 2019 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Aggarwal, Sadhna Verma, Sumit Singh Aggarwal, Sumit Gupta, Subash Chandra Drug repurposing for breast cancer therapy: Old weapon for new battle |
title | Drug repurposing for breast cancer therapy: Old weapon for new battle |
title_full | Drug repurposing for breast cancer therapy: Old weapon for new battle |
title_fullStr | Drug repurposing for breast cancer therapy: Old weapon for new battle |
title_full_unstemmed | Drug repurposing for breast cancer therapy: Old weapon for new battle |
title_short | Drug repurposing for breast cancer therapy: Old weapon for new battle |
title_sort | drug repurposing for breast cancer therapy: old weapon for new battle |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128772/ https://www.ncbi.nlm.nih.gov/pubmed/31550502 http://dx.doi.org/10.1016/j.semcancer.2019.09.012 |
work_keys_str_mv | AT aggarwalsadhna drugrepurposingforbreastcancertherapyoldweaponfornewbattle AT vermasumitsingh drugrepurposingforbreastcancertherapyoldweaponfornewbattle AT aggarwalsumit drugrepurposingforbreastcancertherapyoldweaponfornewbattle AT guptasubashchandra drugrepurposingforbreastcancertherapyoldweaponfornewbattle |